Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy are holding back sales at the pharma ...

Last year, these treatments accounted for 75% of the $236B in annual sales set to vanish with the loss of exclusivity.

President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...